While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the market? This article walks through what the current numbers may be telling ...

The raise comes less than two months after Ricursive was launched by former Google LLC researchers Anna Goldie and Azalia ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Bitcoin's deflationary nature makes it unsuitable as a global currency but ideal for long-term wealth preservation and ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

ChatGPT’s newest model has been caught leaning on Grokipedia, an AI-written encyclopedia created by Elon Musk’s xAI, to ...